Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Multicenter Dose Escalation Study of Carfilzomib With Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma

NCT00603447 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00603447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00603447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Multicenter Dose Escalation Study of Carfilzomib With Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2008
Completion date
January 31, 2016
Enrollment
84 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed multiple myeloma